About Us

Procyon Corporation (PCYN:OB) is a holding company for its subsidiary Amerx HealthCare Corporation which was acquired in 1996.    Amerx develops and markets advanced proprietary skin and wound care products used in the treatment of wounds, ulcers, burns, surgical incisions, cuts, scrapes, abrasions, dermatitis, inflammation and other skin problems.  Amerx provides skin and wound care products through its proprietary brand, Amerigel®.  Amerigel® contains the proprietary antimicrobial agent, Oakin®, proven effective against bacteria commonly found in wounds including MRSA.  Manufacturing and packaging activities are performed pursuant to current good manufacturing practices (CGMP) as defined under the United States Federal Food, Drug and Cosmetic Act (FFDC Act) .  Amerx  products are registered with the Food & Drug Administration (FDA) and receive National Drug Codes (NDC).  Amerx’s sales practices are subject to regulation by the Federal Trade Commission (FTC), the FDA and state agencies.  (Click here to visit the Amerigel website).

Procyon Corporation is a publically traded reporting company, with common shares registered with the  United States Securities and Exchange Commission and which are quoted on the OTC Bulletin Board.    Please refer to the Investor Relations/SEC Filings section of this website to review recent SEC filings.

Global Market –

The global market for wound care products is “projected to reach US $20.3 billion by 2105” according to a recent “Global Strategic Business Report” by Global Industry Analysts, Inc.*

“This market is driven by an aging population, rising incidence of modern epidemics such as diabetes, development of innovative and cost-effective advanced products, along with the need for curbing healthcare costs.”

Amerigel®’s advanced skin and wound care products fit neatly into this global projection.  Amerigel® products are competitively priced and efficacious as proven by clinical research, case studies and in-vitro laboratory studies.  Amerigel® products are widely used by healthcare providers who specialize in lower extremity skin and wound conditions and are attested to by practitioners.

*”Global Strategic Business Report” by Global Industry Analysts, Inc. (GIA), www.StrategyR.com, September 14, 2010.